Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0D2TZ
|
||||
Former ID |
DIB011044
|
||||
Drug Name |
CMS-024-02
|
||||
Synonyms |
Tyroserleutide; Tyroservatide; CMS-024; CMS-024); Tyroserleutide (iv, cancer), China Medical System; Tyroserleutide (iv, cancer), Shenzhen Kangzhe Pharmaceuticals; Tyroservatide (cancer), Shenzhen Kangzhe Pharmaceuticals/ China Medical System Holdings; Tyroserleutide (iv, cancer), Shenzhen Kangzhe Pharmaceuticals/ China Medical System; Tyrosyl-seryl-leucine (cancer), Tianjin Medical University/Shenzhen Kangzhe Pharmaceutical
|
||||
Indication | Cancer [ICD9: 140-229; ICD10:C00-C96] | Phase 3 | [523721] | ||
Company |
Shenzhen Kangzhe Pharmaceutical Co Ltd
|
||||
Structure |
Download2D MOL |
||||
Canonical SMILES |
N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)CC(C)C)CO)Cc1ccc(<br />cc1)O
|
||||
Target and Pathway | |||||
Target(s) | Histone deacetylase | Target Info | Modulator | [550907] | |
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.